NCT01434602 2022-06-01
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
Novartis